Volume 4 Supplement 1

3rd Pediatric Allergy and Asthma Meeting (PAAM)

Open Access

P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children

  • Katrine B Spangenberg1,
  • Inger Merete Jørgensen1,
  • Susanne Halken1,
  • Lone Agertoft1,
  • Frederik Buchwald1,
  • Sune Rubak1,
  • Margrethe Friberg1,
  • Henrik Fomsgaard Kjær1,
  • Thomas Petersen Houmann1 and
  • Thomas Kongstad1
Clinical and Translational Allergy20144(Suppl 1):P142


Published: 28 February 2014


In Denmark, Omalizumab is approved for treating children with severe persistent allergic asthma older than 6 years of age. No systematic registration of the efficacy in the Danish child population according to asthma symptoms or the efficacy on co-morbid allergic symptoms exists. A broad panel of outcome measures is necessary to evaluate the efficacy of Omalizumab treatment.


To provide a standardized systematic registration in order to create a database enrolling children with severe allergic asthma treated with Omalizumab.

Method and study design

A national multicenter registration and follow-up study based on children with clinical persistent severe allergic asthma including both retrospective and prospective registration.

Inclusion criteria

Children, 6-18 years of age, with severe persistent allergic asthma according to GINA treated with Omalizumab.

Outcome registration

A broad panel of outcome measures is scheduled at baseline and during treatment:


  • Asthma exacerbations

  • Hospitalizations

  • Medication

  • Lung function

  • ACT score

  • Peak-flow

  • FeNO

  • Mannitol/Methacholin test

  • Skin prick-test

  • Quality of life score. (Juniper)

  • Rhinitis score, R-RTSS

  • SCORAD score

The monitoring plan and follow-up programme will be presented in a flowchart.


We believe that a national systematic registration will increase knowledge regarding efficacy of Omalizumab treatment in this rare group of severe allergic asthmatic children.

Authors’ Affiliations

Pediatric Department, Hillerød University Hospital


© Spangenberg et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.